Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer. DUO-E evaluated the addition of durvalumab to standard first-line carboplatin/paclitaxel, followed by maintenance durvalumab with or without olaparib, in patients with advanced endometrial cancer. Results were presented at the ESMO Congress 2023 (Abstract LBA41) and simultaneously published in the Journal of Clinical Oncology.
